IP Library Granted Patent US 9,527,897
Granted Patent B2
US 9,527,897 · App. 14/968,198 · Granted Dec 27, 2016

CD40L collectin fusion proteins and encoding nucleic acid molecules

Inventors: Oliver Hill (Neckarsteinach, DE); Christian Gieffers (Dossenheim, DE); Meinolf Thiemann (Schriesheim, DE); Marcus Branschädel (Heidelberg, DE)
Assignee: Apogenix AG
C07K14/525C07K14/42C07K14/4726C07K14/70575C12N15/62C07K2319/00C07K2319/32C07K2319/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,527,897
App. No.
14/968,198
Granted
Dec 27, 2016
Kind
B2
Abstract

The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.

Claims (25)

1. A fusion protein comprising:

(i) a TNF (tumor necrosis factor)-superfamily cytokine of CD40 ligand (CD40L) or a receptor binding domain thereof, and

(ii) a collectin trimerization domain comprising a neck domain or a neck and carbohydrate binding domain of surfactant protein-D,

wherein (ii) is located C-terminally of (i).

2. The fusion protein of claim 1 , additionally comprising a flexible linker between (i) and (ii), wherein the flexible linker is a glycine/serine linker and has a length of 3-20 amino acids.

3. The fusion protein of claim 2 , wherein the flexible linker has the amino acid sequence of SEQ ID NO: 53, which is (GSS) a (SSG) b (GSG) c wherein a, b, c is each 0, 1, 2, 3, 4, 5 or 6.

4. The fusion protein of claim 2 , wherein the flexible linker has a length of 9-15 amino acids.

5. The fusion protein of claim 1 , wherein the CD40L has the sequence of SEQ ID NO:5.

6. The fusion protein of claim 1 , wherein (i) comprises amino acids 112-261 or 117-261 of a human CD40L of SEQ ID NO:5.

7. The fusion protein of claim 1 , wherein (ii) comprises amino acids 217-375, 218-375, 219-375, 220-375, 221-375, 222-375, 223-375, 224-375, or 225-375 of a human surfactant protein-D of SEQ ID NO:21.

8. The fusion protein of claim 1 , wherein (ii) comprises amino acids 217-257, 218-257, 219-257, 220-257, 221-257, 222-257, 223-257, 224-257, or 225-257 of a human surfactant protein-D of SEQ ID NO:21.

9. The fusion protein of claim 1 , wherein (ii) comprises a mutant of human surfactant protein-D of SEQ ID NO:21 having only one amino acid substitution.

10. The fusion protein of claim 9 , wherein the amino acid substitution affects amino acid position F355 of SEQ ID NO:21, and the amino acid substitution is one of the following: F355A, F355S, F355T, F355E, F355D, F355K, or F355R.

11. The fusion protein of claim 9 , wherein (ii) comprises a mutant which does not bind to mannose.

12. The fusion protein of claim 1 , which additionally comprises an N-terminal signal peptide domain.

13. The fusion protein of claim 1 , wherein the fusion protein further comprises a recognition/purification domain located at the N-terminus or at the C-terminus.

14. The fusion protein of claim 13 , wherein the recognition/purification domain is a Strep-tag or a poly His-domain.

15. The fusion protein of claim 1 , which additionally comprises a C-terminal flexible element.

16. A trimeric complex comprising three fusion proteins of claim 1 .

17. The trimeric complex of claim 16 , wherein the complex is formed by covalent linkage between the three fusion proteins.

18. The trimeric complex of claim 17 , wherein the complex consists of three identical fusion proteins.

19. A nucleic acid molecule encoding the fusion protein of claim 1 .

20. The nucleic acid molecule of claim 19 , which is operatively linked to an expression control sequence.

21. A vector comprising the nucleic acid molecule of claim 20 .

22. An isolated cell transformed or transfected with the nucleic acid molecule of claim 20 .

Assignments (1)
CHANGE OF NAME Recorded Mar 21, 2016
From: APOGENIX GMBH
To: APOGENIX AG
Reel/Frame 038190/0226 →
Priority Claims (1)
EP 07013506 · Jul 10, 2007 · regional
Continuity (4)
Continuation 14322830 · Jul 2, 2014
Continuation 13776559 · Feb 25, 2013
Continuation 12668188
Related Publication 20160176941A1 · Jun 23, 2016